Long term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): A randomised study

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 104, Issue 6, 1997, Pages 708-717

  Hänggi, Willy ^a   Lippuner, Kurt ^b   Riesen, Walter ^c   Jaeger, Phillippe ^b   Birkhauser, Martin H ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; DYDROGESTERONE; ESTRADIOL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TIBOLONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HORMONE SUBSTITUTION; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; DYDROGESTERONE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LIPOPROTEINS; MIDDLE AGED; NORPREGNENES; PROGESTERONE CONGENERS;

EID: 0031011064     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1997.tb11982.x     Document Type: Article

References (58)

1. Bush TL, Barrett-Connor E, Cowan LD et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the lipid research clinics program follow-up study. Circulation 1987; 75: 1102–1109.
2. Henderson BE, Ross RK, Paganini-Hill A, Mack TM. Estrogen use and cardiovascular disease. Am J Obstet Gynecol 1986; 154: 1181–1186.
3. Stampfer MJ, Colditz GA, Willett WC et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991; 325: 756–762.
4. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196–1204.
5. Whitehead MI, King RJB, McQueen J, Campbell S. Endometrial histology and biochemistry in climacteric women during oestrogen and oestrogen/progestogen therapy. J Roy Soc Med 1979; 72: 322–327.
6. Gambrell RD Jr. Prevention of endometrial cancer with progestogens. Maturitas 1986; 8: 159–168.
7. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, Van Belle G. Progestogen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338: 274–277.
8. Lobo RA. Clinical review 27: effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 1991; 73: 925–930.
9. Whitehead MI, Hillard TC, Crook D. The role and use of progestogens. Obstet Gynecol 1990; 75: 59S–76S.
10. Ettinger B, Genant HK, Steiger P, Madvig P. Low-dosage micronized 17β-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 1992; 166: 479–488.
11. Marchesoni D, Fiscon D, Bologna A, Dal Pozzo M, Dal Magro L, Mozzanega B. Transdermal estrogen therapy in menopause. Eighteen months follow-up. Clin Exp Obstet Gynecol 1991; 18: 281–285.
12. Crook D, Godsland IF, Hull J, Stevenson JC. Hormone replacement therapy with dydrogesterone and 17β-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. Br J Obstet Gynaecol 1997; 104: 298–304.
13. Siddle NC, Jesinger DK, Whitehead MI, Turner P, Lewis B, Prescott P. Effect on plasma lipids and lipoproteins of postmenopausal oestrogen therapy with added dydrogesterone. Br J Obstet Gynaecol 1990; 97: 1093–1100.
14. van der Mooren MJ, Demacker PNM, Thomas CMG, Bonn GF, Rolland R. A 2-year study on the beneficial effects of 17 b-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone. Eur J Obstet Gynecol Reprod Biol 1993; 52:117–123.
15. Vermorken AJ, Sultan C, Goos CM. Dydrogesterone has no peripheral (anti)-androgenic properties. In Vivo 1987; 1: 167–171.
16. De Visser J, Coert A, Feenstra H, Van Der Vies J. Endocrinological studies with (7a,17a)-17-hydroxy-7-methyl-19-norpregn-5-en-20-yn-3-one(OrgOD 14). Arzneimittelforschung 1984; 34: 1010–1017.
17. Benedek Jaszmann LJ. Long-term placebo-controlled efficacy and safety study of Org OD 14 in climacteric women. Maturitas 1987; Suppl 1: 25–33.
18. Rymer J, Chapman MG, Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporosis Int 1994; 4: 314–319.
19. 3quantitation based on precipitation with polyethylene glycol. Clin Chim Acta 1985; 148: 139–147.
20. Clauss A. Gerinnungs-physiologische Schnellmethode zur Bestim-mung des Fibrinogens. Acta Haematol 1957; 17: 237–246.
21. Statistical Sciences: S-PLUS Guide to Statistical and Mathematical Analysis, Version 3.3. Seattle, USA : StatSci (MathSoft Inc), 1995.
22. Morrison DF. Multivariate Statistical Methods. New York : McGraw-Hill Publishing Company, 1990.
23. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kanel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256: 2835–2838.
24. Ginsburg GS, Safran C, Pasternak RC. Frequency of low serum high-density lipoprotein cholesterol levels in hospitalized patients with ‘desirable’ total cholesterol levels. Am J Cardiol 1991; 86: 187–192.
25. Manninen V, Elo MO, Frick H et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260: 641–651.
26. Crona N, Silfverstolpe G, Samsioe G. A double-blind cross-over study on the effects of Org OD 14 compared to estradiol valerate and placebo on lipid and carbohydrate metabolism in oophorectomized women. Acta Endocrinol 1983; 102: 451–455.
27. Kloosterboer HJ, Benedek Jaszmann LJ, Kicovic PM. Long-term effects of Org OD 14 on lipid metabolism in post-menopausal women. Maturitasi 1990; 12: 37–42.
28. Netelenbos JC, Siregar Emck MT, Schot LP, Van Ginkel FC, Lips P, Leeuwenkamp OR. Short-term effects of Org OD 14 and 17 beta-oestradiol on bone and lipid metabolism in early post-menopausal women. Maturitas 1991; 13: 137–149.
29. Walker ID, Davidson JF, Richards A, Yates R, McEwan HP. The effect of the synthetic steroid Org OD 14 on fibrinolysis and blood lipids in postmenopausal women. Thromb Haemost 1985; 53: 303–305.
30. Adami A, Rossini M, Zamberlan N, Bertoldo F, Dorizzi R, Lo Cascio V. Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women. Maturitas 1993; 17: 191–196.
31. 2 cholesterol in nor-molipidemic men with coronary artery disease. Arterioscler Thromb Vasc Biol 1995; 15: 1043–1048.
32. Drexel H, Ammann FW, Rentsch K et al. Relation of the level of high-density lipoprotein subtractions to the presence and extent of coronary artery disease. Am J Cardiol 1992; 70: 436–440.
33. Steenkamp HJ, Jooste PL, Bande AJ, Langenhoven ML, Rossouw JE. Relationship between high density lipoprotein subtractions and coronary risk factors in a rural white population. Arteriosclerosis 1992; 10: 1026–1031.
34. Erkkola RU, Hirvonen EJ, Juntunen SST et aL Comparison of trans-dermal to oral hormone replacement therapy. Eur Menopause J 1995; 2: 21–27.
35. van der Mooren MJ, Demacker PN, Thomas CM, Rolland R. Beneficial effects on serum lipoproteins by 17 beta-oestradiol-dydro-gesterone therapy in postmenopausal women; a prospective study. Eur J Obstet Gynecol Reprod Biol 1992; 47: 153–160.
36. Cortellaro M, Nencioni T, Boschetti C et al. Cyclic hormonal replacement therapy after the menopause: transdermal versus oral treatment Eur J Clin Pharmacol 1991; 41: 555–559.
37. Moorjani S, Dupont A, Labrie F et al. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J Clin Endocrinol Metab 1991; 73: 373–379.
38. Kissebah AH, Harrigan P, Wynn V. Mechanism of hypertriglyceri-daemia associated with contraceptive steroids. Horm Metab Res 1973; 5: 184–190.
39. Crook D, Cust MP, Gangar KF et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992; 166: 950–955.
40. Bengtsson C, Bjorkelund C, Lapidus L, Lissner L. Associations of serum lipid concentrations and obesity with mortality in women: 20 year follow up of participants in prospective population study in Gothenburg, Sweden. BMJ 1993; 307: 1385–1388.
41. Carlson LA, Bottiger LE. Risk factors for ischaemic heart disease in men and women. Results of the 19-year follow-up of the Stockholm prospective study. Acta Med Scand 1985; 218: 207–211.
42. Lapidus L, Bengtsson C, Lindquist O, Sigurdsson JA, Rybo E. Triglycerides—triglycermain lipid risk factor for cardiovascular disease in women Acta Med Scand 1985; 217: 481–489.
43. Stensvold I, Tverdal A, Urdal P, Graff-Iversen S. Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. BMJ 1993; 307: 1318–1322.
44. Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions. The association between triglycerides and coronary heart disease. N Engl J Med 1980; 302: 1383–1389.
45. Lobo RA, Speroff L. International consensus conference on postmen-opausal hormone therapy and the cardiovascular system. Fertil Steril 1994; 61: 592–595.
46. Parish E, Barnes JF, Rolton HA, Spowart K, Fletcher CD, Hart DM. Effects of tibolone on lipoprotein(a) and HDL subtractions. Maturitas 1995; 20: 215–219.
47. Haenggi W, Riesen W, Birkhäuser MH. Postmenopausal hormone replacement therapy with Tibolone decreases serum lipoprotein(a). Eur J Clin Chem Clin Biochem 1993; 31: 645–650.
48. Rymer J, Crook D, Sidhu M, Chapman M, Stevenson JC. Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women. Acta Endocrinol 1993; 128: 259–262.
49. Soma M, Fumagalli R, Paoletti R et al. Plasma Lp(a) concentration after oestrogen and progestogen in postmenopausal women [letter], Lancet 1991; 337: 612.
50. Meusing RA, Miller VT, Mills TA, Larosa JC. Effects of postmenopausal unopposed estrogen and combined therapy on lipoprotein(a) levels. Arteriosclerosis Thromb 1991; 11: 1452a.
51. Nabulsi AA, Folsom AR, White A et al. Association of hormone replacement therapy with cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069–1075.
52. Lobo RA, Notelovitz M, Bernstein L, Khan FY, Ross RK, Paul WL. Lp(a) lipoprotein: relationship to cardiovascular disease risk factors, exercise and estrogen. Am J Obstet Gynecol 1992; 166: 1182–1190.
53. Parish E, Rolton HA, Barnes JF, Hart DM. Lipoprotein(a) concentrations in postmenopausal women taking norethisterone. BMJ 1991; 303: 694.
54. Albers JJ, Taggart HM, Applebaum-Bowden D, Haffner S, Chesnut CH, Hazzard WR. Reduction of lecithin-cholesterol acyl-transferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanazolol. Biochem Biophys Acta 1984; 795: 293–296.
55. Crook D, Sidhu M, Seed M, O'Donnell M, Stevenson JC. Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid. Arteriosclerosis 1992; 92: 41–47.
56. McLean JW, Tomlinson JE, Kuang WJ. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 300: 132–137.
57. Meade TW, Cooper J, Miller GJ, Howarth DJ, Stirling Y. Antithrombin III and arterial disease. Lancet 1991; 338: 850–851.
58. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47–63.